Oramed Pharmaceuticals Announces Maiden Year Progress Report
14 March 2007 - 5:50AM
PR Newswire (US)
JERUSALEM, March 13 /PRNewswire-FirstCall/ -- Oramed
Pharmaceuticals Inc. (OTC:ORMPOTC:FTSE:OTC:OJU) (BULLETIN BOARD:
ORMP, FTSE: OJU) , an Israel based company, is proud to announce
its 1 year anniversary and accomplishments. CEO Nadav Kidron
states, "Over the past year we have hit many great milestones for
our supporting shareholders including surpassing the International
Review Board and Ministry of Health approvals to further our
initial flagship product, oral insulin, toward human clinical
trials. In addition, we were able to gain the support of Swiss
Caps, one of the largest manufacturers of soft gel capsules in the
world, to accept us as a client and to support our company with
their validation of our technology in producing our capsules for a
direct share exchange in lieu of a cash payment. Between the end of
2006 and the beginning of 2007, we approached and succeeded in
building an internationally known scientific board, containing very
strong contacts within the NIH (National Institution of Health),
ADA (American Diabetes Association), Hadassah Research Hospital,
and many other well-known institutions both professional and
educational. Their expertise expands within Endocrinology,
Immunology, Diabetes and Medicinal practices globally, with
strengths in greater Europe, South Africa, and North America This
has enabled us to further our horizons and focus on innovations in
medicinal research. Within our first year, Oramed is in the process
of registering I.P. over another method of Insulin delivery. In
addition, we have begun pre clinical testing on an oral replacement
for the highly demanded flu vaccine, with over a billion doses
disseminated annually, as reported by the CDC. We are pragmatically
enhancing our pipeline to incorporate new technologies to help take
the pinch out of life for many suffering patients with debilitating
diseases as well as enable a larger percentage of the population to
take necessary vaccinations and maintain a healthier lifestyle. We
look forward to another strong year of developments and expansion
as we move forward with great hope. For more information on Oramed
Pharmaceuticals please visit our website:
http://www.oramedpharma.com/ Legal Notice Regarding Forward-Looking
Statements This news release contains statements, which may
constitute "forward- looking statements". Those statements include
statements regarding the intent, belief or current expectations of
Oramed Pharmaceutical Inc., and members of our management as well
as the assumptions on which such statements are based.
Forward-looking statements in this release include: that Oramed is
in the process of registering I.P. over another method of Insulin
delivery; that we have begun pre clinical testing on an oral
replacement for the highly demanded flu vaccine, with over a
billion doses disseminated annually; that we are enhancing our
pipeline to incorporate new technologies to help take the pinch out
of life for many suffering patients with debilitating diseases as
well as enable a larger percentage of the population to take
necessary vaccinations and maintain a healthier lifestyle; and that
we hope to have another strong year of developments and expansion..
Factors which may significantly change or prevent our forward
looking statements from fruition include that we may be
unsuccessful in developing any products; we may be unable to raise
funds and resources to pursue research and development; our patent
applications may not be accepted by the patent office; we may be
unable to successfully defend our patents from infringement by
third parties, there is a risk that our patents may be subsequently
shown to be invalid or infringe the patents of others, our products
may never gain FDA or other regulatory body approval for human
consumption and we may be unable to successfully commercialize our
future products. Readers should refer to our most recent period
reports filed on Edgar. Investor Relations Contact: Oramed
Pharmaceuticals, Inc. Vinisha Agnihotri (646) 467-2252
http://www.oramedpharma.com/ DATASOURCE: Oramed Pharmaceuticals,
Inc. CONTACT: Investor Relations Contact - Vinisha Agnihotri,
Oramed Pharmaceuticals, Inc., +1-646-467-2252, Web site:
http://www.oramedpharma.com/
Copyright